Open an account

Scienture Holdings

SCNX · NASDAQ

$3.05+$0.13 (+4.45%)TodayMarket closed ·
Prev close $2.92

About SCNX

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 4 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees
4
Headquarters
Commack, New York
Listed
Feb 18, 2020
Sector
Health Care
Industry
Health Care Technology
Website
trxadehealth.com

SCNX key statistics

Market cap
5.01M
Price-earnings ratio
0.00
Dividend yield
44.25%
Average volume
417.10K
Volume
22.50K
Open price
$2.92
High today
$3.05
Low today
$2.92
52 Week high
$65.00
52 Week low
$2.81

Scienture Holdings (SCNX) at a glance

As of Oct 20, 2026, Scienture Holdings (SCNX) shares are priced at $3.05, giving the company a market cap of 5.01M, a price-to-earnings ratio of 0.00 and a dividend yield of 44.25%.

Today the stock has traded between $2.92 and $3.05. The current price is 4.4% above the day's low and 0.0% below its high.

Volume so far is 22.50K shares, below the average of 417.10K shares a day.

Over the past year Scienture Holdings has ranged from $2.81 to $65.00, and now sits 0% of the way up that range.

Scienture Holdings met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.75 per share against an estimate of -$5.86.

The average analyst price target is $1.53, 49.8% below the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $1.53
Low
$1.51
Now
$3.05
High
$1.58

SCNX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 66.4% on average.

  1. Q2 FY22: reported -$1.95 per share against an estimate of -$1.53
  2. Q3 FY22: reported -$0.90 per share against an estimate of -$1.84
  3. Q4 FY22: reported -$0.15 per share against an estimate of -$0.9945
  4. Q1 FY23: reported -$1.05 per share against an estimate of -$0.459
  5. Q2 FY23: reported -$2.90 per share against an estimate of -$0.765
  6. Q4 FY25: reported -$0.11 per share against an estimate of -$0.2856
  7. Q1 FY26: reported -$2.00 per share against an estimate of -$5.61
  8. Q2 FY26: reported -$1.75 per share against an estimate of -$5.86

SCNX news

  • Vandana Singh

    EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

  • Vandana Singh

    EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions

  • Tanya Rawat

    Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Vandana Singh

    EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

  • Mohd Haider

    Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why

  • FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose

  • Vandana Singh

    EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Similar companies

Companies in the same industry as Scienture Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.